New treatments for lung disease related to systemic sclerosis
Official title: Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease
Funded at Eydis Bio, INC. · NIH-10920991 · Data updated 2026-11-12
This study is testing a new treatment for people with systemic sclerosis-related lung disease, aiming to help reduce lung inflammation and scarring by targeting a specific protein, and it has shown promising results in early tests.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eydis Bio, INC. NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | July 15, 2024 |
| Project end | July 14, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,182,632 |
| NIH project number | 1R44HL170834-01A1 |
| Project ID | NIH-10920991 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with systemic sclerosis-associated interstitial lung disease.
✕Less likely to help
Patients with other forms of lung disease unrelated to systemic sclerosis may not benefit from this research.
What this research studies
This research focuses on developing new compounds to treat systemic sclerosis-associated interstitial lung disease (SSc-ILD), a serious condition that causes lung fibrosis and has a high mortality rate. The study aims to target a specific protein, TAK1, which is involved in the inflammatory and fibrotic processes of the disease. By creating a potent and selective inhibitor called HS-276, the researchers hope to reduce lung inflammation and fibrosis in patients. The research involves preclinical studies that have shown promising results in reducing lung damage in models of the disease.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients suffering from SSc-ILD.
How similar studies have gone: Other research has shown success in targeting similar pathways for treating fibrotic diseases, indicating potential for this novel approach.
Where this research is happening
-
Eydis Bio, INC.
Durham, United States Active
Researchers
- Principal investigator: Scarneo, Scott — Eydis Bio, INC.
- Study coordinator: Scarneo, Scott
Related research
Other NIH-funded projects on the same topics.
-
Understanding how a cell protein (SLC9A1) drives skin and lung scarring in systemic sclerosis
A five-year NIH grant aims to understand how a specific cell protein called SLC9A1 influences scar-forming cells in systemic sclerosis and related lung disease, with the goal of finding possible therapies.
-
From proteins and genes to new treatments for scar-related lung disease
A large NIH grant is working to map the proteins in the lungs of people with systemic sclerosis to find new targets for drugs that could slow or stop lung fibrosis.
-
Vasculopathy in Systemic Sclerosis and Lung Disease in Adults
A study in adults with systemic sclerosis will look at how blood vessels in the lungs and body relate to the development of lung disease, with the aim of finding new ways to prevent it.
-
Functional markers to guide treatment in systemic sclerosis–related lung disease
A research grant at USC is studying blood biomarkers that show whether medicines are helping people with systemic sclerosis–related interstitial lung disease.
-
Systemic sclerosis-related lung disease: who’s at risk and what blood markers hint at it
A dedicated research grant asks how to identify which people with systemic sclerosis will develop interstitial lung disease and which blood biomarkers can signal that risk.
-
New treatments for lung scarring in systemic sclerosis
This project looks for new drug targets and therapies to help people with systemic sclerosis who have scarring in their lungs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.